Recent data from an Amgen obesity-drug trial only reinforced investors' impressions that Eli Lilly and Novo Nordisk have a prohibitive head start, thanks, in particular, to a new generation of Lilly ...

Piper Sandler has initiated coverage of Corbus Pharmaceuticals (NASDAQ:CRBP) and Viking Therapeutics (NASDAQ:VKTX) with ...

GLP-1R injectable drugs are effective in treating obesity, but their success points to a gap in the market: oral alternatives.

The price of Wegovy, the diabetes control drug's glamorous anti-obesity sibling, may also be falling, according to a Health ...

Novo Nordisk A/S (NYSE:NVO) is a Danish multinational pharmaceutical company that specializes in the discovery, development, ...

After losing and regaining the same 20-plus pounds more times than she could count, Anita Blanchard concluded that diets ...

More than 7 million Americans struggling with obesity would become eligible for coverage under the proposed change ...

Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

The biotech industry can be volatile even for relatively large companies. Amgen ( AMGN 1.00%), one of the more prominent names in the game, just reminded us all of that fact. On Nov. 26, the company's ...

Unless you have been living under a rock, you’ll know that anti-obesity GLP-1 drugs are the next big thing in pharma, with ...